<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361424</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-PXT00864-03</org_study_id>
    <nct_id>NCT02361424</nct_id>
  </id_info>
  <brief_title>Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)</brief_title>
  <acronym>PLEODIAL-I</acronym>
  <official_title>First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharnext SA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ascopharm Groupe Novasco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharnext SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy on cognitive impairment and&#xD;
      functioning of several doses of PXT00864 (new fixed combination of acamprosate and baclofen&#xD;
      at low dose) in patients with mild Alzheimer Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the total score of the 11-item Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
    <description>Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater cognitive impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>throughout the 12-week study period.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
    <description>Scores on the DSST range from 0-93 with lower scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the speed to perform the Zazzo's Cancellation Test</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Zazzo's Cancellation Test</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the 15-second Isaacs Set Test</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the time score of the Trail Making Test - part A</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the time score of the Trail Making Test - part B</measure>
    <time_frame>Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Free and Cued Selective Reminding Test (FCSRT)</measure>
    <time_frame>1 (baseline) and V4 (end of study, after 12 weeks of treatment)</time_frame>
    <description>FCSRT is a memory test administered according to the procedure described by Gröber and Buschke modified with 16 verbal items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the 4-item Instrumental Activities of Daily Living scale (IADL-PAQUID)</measure>
    <time_frame>V0 (train), V1 (baseline), and every 4 weeks (V2, V3 and V4)</time_frame>
    <description>The 4-item Instrumental Activities of Daily Living scale (IADL) concerns four routine daily functions (using transportation, managing finances, using the phone and managing medicines use). Scores on the IADL range from 4-15 with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Clinical Dementia Rating (CDR) scale</measure>
    <time_frame>1 (baseline) and V4 (end of study, after 12 weeks of treatment)</time_frame>
    <description>The Sum of Boxes score of the CDR ranges from 0 to 18, with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the score of the Apathy Inventory (AI) scale</measure>
    <time_frame>1 (baseline) and V4 (end of study, after 12 weeks of treatment)</time_frame>
    <description>Scores on the AI range from 0-12 with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in the cognitive Event Related Potential parameters (optional)</measure>
    <time_frame>V1 (baseline), and every 4 weeks (V2, V3 and V4)</time_frame>
    <description>Some cognitive Event Related Potentials (ERP) with auditory oddball paradigm are performed as an ancillary study.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>PXT00864 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT00864 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .&#xD;
These 2 capsules are taken orally b.i.d. during 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXT00864 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .&#xD;
These 2 capsules are taken orally b.i.d. during 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of PXT00864</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .&#xD;
These 2 capsules are taken orally b.i.d. during 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT00864</intervention_name>
    <description>PXT00864 is a fixed-dose combination of baclofen and acamprosate</description>
    <arm_group_label>PXT00864 Dose 1</arm_group_label>
    <arm_group_label>PXT00864 Dose 2</arm_group_label>
    <arm_group_label>PXT00864 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo of PXT00864</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged ≥ 60 years.&#xD;
&#xD;
          -  Patient with a diagnosis of probable AD&#xD;
&#xD;
          -  Progressive decline in cognition for more than six months which story is documented in&#xD;
             patient medical records&#xD;
&#xD;
          -  A Mini-Mental State Examination (MMSE) score of 20-26&#xD;
&#xD;
          -  With a minimum of educational background&#xD;
&#xD;
          -  Naïve to anti-dementia treatment&#xD;
&#xD;
          -  MRI assessment which corroborates the clinical diagnosis (hippocampal atrophy) and&#xD;
             excludes other potential causes of dementia especially cerebrovascular lesions&#xD;
&#xD;
          -  If available, Cerebral Spinal Fluid (CSF) classical biomarkers should be at levels&#xD;
             which corroborate the clinical diagnosis&#xD;
&#xD;
          -  Ambulatory patient living at home with a caregiver available and living in the same&#xD;
             household or interacting with the patient daily and available if necessary to ensure&#xD;
             administration of the investigational product&#xD;
&#xD;
          -  Absence of major or severe depressive disease&#xD;
&#xD;
          -  Patient with a willingness to participate in this study and who have signed an&#xD;
             informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Early onset of dementia, i.e. before 60 years old to avoid hereditary AD forms&#xD;
&#xD;
          -  Significant neurological disease other than AD&#xD;
&#xD;
          -  Major psychiatric disorder or syndrome (schizophrenia or bipolar disorder)&#xD;
&#xD;
          -  Seizure disorders&#xD;
&#xD;
          -  Other infectious, metabolic or systemic diseases affecting central nervous system&#xD;
&#xD;
          -  Other active clinically significant illness&#xD;
&#xD;
          -  Hospitalization or change of chronic concomitant medications one month prior to&#xD;
             screening&#xD;
&#xD;
          -  Patients with severe respiratory, hepatic or renal failure or with any other&#xD;
             significantly potentially disabling abnormality detected during screening&#xD;
&#xD;
          -  Known hypersensitivity to the tested treatment including active substance and&#xD;
             excipients.&#xD;
&#xD;
          -  Patients participating in another study and exposed to any investigational therapy&#xD;
             within the 30 days prior to the entry in this study.&#xD;
&#xD;
          -  Patient without medical care insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Orgogozo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Pellegrin, Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMRR</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PXT00864</keyword>
  <keyword>mild AD</keyword>
  <keyword>phase 2a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

